NasdaqGS:JAZZPharmaceuticals
Jazz Pharmaceuticals (JAZZ): Evaluating Valuation After Accelerated FDA, NCCN Approvals for Brain Cancer Therapy
If you are tracking Jazz Pharmaceuticals (JAZZ), the past few weeks have been especially interesting. The company’s new brain cancer therapy, Modeyso, just cleared two high-profile hurdles: first, the FDA granted it accelerated approval for treating difficult-to-manage gliomas; now, the National Comprehensive Cancer Network has endorsed Modeyso as a category 2A single-agent option for both adults and children. This double boost means more doctors may consider Modeyso for a wider group of...